Quadrivalent vaccine against HPV and prevention of anogenital diseases

Key points on our paper are the following:

•  In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated cervical dysplasia from these vaccine related HPV types. The prevention of  the precancerous lesions of CIN 2/3 are thus surrogates for prevention of cervical cancer
• In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated vaginal and or vulvar intraepithelial neoplasias grade 2/3, surrogate markers for vaginal and vulval cancers.
• In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated external anogenital warts
• In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated adenocarcinoma in situ grade 2/3,  the precancerous lesions of adenocarcinoma, a cancer poorly predicted by Pap screening cytology  
• In young women previously infected with any of HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated disease from those vaccine related HPV types to which they have not been previously infected. I.e. a woman may had previous types six, but with the vaccine is equally protected to 16, 18 and 11 and as compared to a woman completely naïve to all four viruses

Bibliographic reference:

Garland SM et al.: "Quadrivalent vaccine against the human papillovmavirus to prevent anogenital diseases", N Engl J Med 2007 May; 356:1928-1943 

Suzanne Garland